Malaria Vaccine R&D in the Decade of Vaccines: Breakthroughs, Challenges and Opportunities
While progress has been made in reducing malaria mortality with other interventions, vaccines are still urgently needed to further reduce the incidence of clinical disease. The most clinically advanced candidate, RTS,S, is presently undergoing Phase 3 evaluation, and the development of more highly efficacious vaccines to prevent clinical disease caused by both P. falciparum and Plasmodium vivax, as well as vaccines to support elimination efforts by inducing immunity that blocks malaria parasite transmission, are priorities. This article, published in the Vaccine supplement, provides information on breakthroughs and opportunities in the field of malaria vaccine research and development, as well as key challenges being faced.
Author(s): Birkett AJ, Moorthy VS, Loucq C, Chitnis CE, Kaslow DC
Visit web page (English)
697 KB PDF (Located at www.sciencedirect.com)
Birkett AJ, Moorthy VS, Loucq C, Chitnis CE, Kaslow DC. Malaria Vaccine R&D in the Decade of Vaccines: Breakthroughs, Challenges and Opportunities. Vaccine. 2013;31(2):B233-B243.